The QualityStocks Daily Wednesday, August 7th, 2024

Today's Top 3 Investment Newsletters

TradersPro(GTHX) $7.0600 +66.12%

MarketClub Analysis(PETQ) $30.4200 +47.89%

StockEarnings(UPST) $33.3000 +39.51%

The QualityStocks Daily Stock List

Salarius Pharmaceuticals (SLRX)

QualityStocks, StockMarketWatch, Stocks That Move, MarketBeat, StocksEarning, Premium Stock Alerts, Money Wealth Matters and 360 Wall Street reported earlier on Salarius Pharmaceuticals (SLRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) (FRA: FP11) is a clinical stage biotechnology firm that is engaged in the development of cancer treatments that are epigenetic-based. Epigenetic refers to the regulatory system that influences gene expression.

Salarius Pharmaceuticals Inc. operates in the biotechnology industry, under the healthcare sector and is based in Houston, Texas. The firm, which was known as Flex Pharma Inc. before changing its name has been granted Product Development Award funding that totals $18.7 million by the Cancer Prevention and Research Institute of Texas in addition to other funding by the National Pediatric Cancer Foundation for the advancement of the Ewing sarcoma clinical program. Salarius Pharmaceuticals Inc. serves consumers and patients in the U.S. and was established in 2014.

Salarius Pharmaceuticals is party to strategic partnerships with the Cancer Prevention and Research Institute of Texas for various activities that entail product development; HLB Life Sciences for the development, manufacture, production and sale of the SP-2577 candidate in South Korea and the University of Utah Research Foundation for the license to patent rights that protect SP-2577 and associated compounds.

Salarius Pharmaceuticals Inc.’s product pipeline includes its lead candidate; seclidemstat, which is undergoing a phase 1/2 clinical trial for relapsed or refractory Ewing sarcoma. The candidate, which is also known as SP-2577, is also undergoing phase 1/2 clinical trials that evaluate its efficacy in treating advanced solid tumors, including ovarian, breast and prostate cancers.

As of 2020, the firm’s SP-2577 candidate had been awarded Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Designation by the FDA. Seclidemstat employs a new approach to treat/improve Ewing sarcoma, which will not only benefit patients by addressing a previously unmet medical need but also extend the firm’s reach in the market, which will be good for its growth and investment opportunities.

Salarius Pharmaceuticals (SLRX), closed Wednesday's trading session at $2.36, up 26.8817%, on 17,341,333 volume. The average volume for the last 3 months is 1.515M and the stock's 52-week low/high is $1.35/$7.904.

T Stamp Inc. (IDAI)

QualityStocks, MarketClub Analysis, MarketBeat, 360wallstreet, Money Wealth Matters, InvestorsUnderground and INO Market Report reported earlier on T Stamp Inc. (IDAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

T Stamp Inc. (NASDAQ: IDAI) is an artificial intelligence firm that is focused on the development and marketing of identity authentication software solutions for peer-to-peer markets and enterprise partners.

The firm has its headquarters in Atlanta, Georgia and was incorporated in 2015 by Mike Lindenau, Catherine Lambert, Andrew Gowasack and Gareth Genner. It operates as part of the software-application industry, under the technology sector. The firm serves consumers across the globe, with a primary focus on the United Kingdom, Malta and the United States.

The enterprise uses the cutting-edge power and agility of technologies like edge computing, neural networks and graphics processing unit to process data effectively for usage in various industries. Its AI-powered solutions include data mining, cryptography, researching and leveraging biometric science, to deliver insightful trust and identity predictions while also guarding against and identifying fraudulent attacks. Its solutions convert identification data like biometrics into a transformed identity token which is used as a secure tokenized identity. It also provides solutions for biometric capture, duplicate detection, identity verification, document validation, data protection and privacy. The enterprise serves the healthcare, travel and real estate; sharing economy, social media and P2P transactions; government and law enforcement; KYC/AML compliance (Know Your Customer/Anti-Money Laundering compliance); biometrically secured email; humanitarian and development services; and the banking/fintech industries.

The company recently entered into a partnership with VIVA Finance, which will involve providing support to equitable and accessible financial systems, as the basis for global inclusion. This move will not only expand the impact and reach of the company’s solutions but also bring in additional investments and revenues.

T Stamp Inc. (IDAI), closed Wednesday's trading session at $0.4497, up 23.9526%, on 65,245,670 volume. The average volume for the last 3 months is 1.036M and the stock's 52-week low/high is $0.30/$3.50.

Color Star Technology (ADD)

Prism MarketView, QualityStocks and Bull Ventures reported earlier on Color Star Technology (ADD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Color Star Technology Co. Ltd (NASDAQ: ADD) (FRA: 2J4A) is an entertainment and education firm that is engaged in the provision of online entertainment performances and music education services.

The firm has its headquarters in New York and was incorporated in 2002. Prior to its name change in May 2020, the firm was known as Huitao Technology Company Limited. It operates as part of the entertainment industry, under the communication services sector. The firm primarily serves consumers in the United States and the People’s Republic of China.

The enterprise focuses on the application of technology and artificial intelligence in the entertainment industry, and primarily offers services through its wholly owned subsidiaries, Color Metaverse Pte. Ltd (Color Metaverse); and CACM Group NY Inc. Color World is its online cultural entertainment platform, which is operated by Color Metaverse. It is a platform that primarily offers celebrity-led education services. The curriculum development created by the enterprise includes sports, music, animation, film and television, painting and calligraphy, life skills and others. Its online store features to its Color World App, with support to sell various products, including clothing, hats, shoes, wine, watches, digital products and other categories. Its star online + entertainment teaching offers a variety of stars and entertainment teaching experience. The enterprise also offers students a professional artist training platform.

The company recently entered into a strategic partnership with Hua Yu Sheng Shi Group, a move that will facilitate the development of new entertainment and sports IPs in the future. This is in addition to extending the company’s consumer reach and creating shareholder value.

Color Star Technology (ADD), closed Wednesday's trading session at $0.4999, up 39.2479%, on 6,172,636 volume. The average volume for the last 3 months is 74,171 and the stock's 52-week low/high is $0.1711/$1.86.

Targa Exploration (TRGEF)

We reported earlier on Targa Exploration (TRGEF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Targa Exploration Corp. (OTCQB: TRGEF) (CNSX: TEX) (FRA: V6Y) is a lithium exploration firm focused on acquiring, exploring for, and developing mineral properties.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2017, on September 26th. Prior to its name change in July 2021, the firm was known as RCM Minerals Limited. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in Canada.

The company’s lithium project portfolio comprises of about 15 projects in the provinces of Quebec, Ontario, Manitoba, and Saskatchewan and covers over 400,000 hectares (ha) of prospective ground. They include the Leaf River Project, Opinaca Project, Pegmatite Beach Project, Musquaro Project, Superior Projects, Ungava Project, Harricana Project, Case Lake Project, Sky Lake Project, Slim Jim Project, Lakeshore Project, Detour West Project, White Metal Project, and Prince-Albert Lake Project. The Opinaca Lithium Property is located within the Opinaca sedimentary basin in James Bay, Quebec. The property covers more than 85,000ha of mineral claims that are 100% owned by the company, subject to a 3% royalty owned by Kenorland Minerals. The Leaf River Project comprises of a pair of individual blocks of mineral claims in the Nunavik region of northern Quebec totaling about 25,636 ha. The company’s gold-silver project in the province of Yukon is the Shanghai Project.

The firm, which recently announced the completion of the next phase of exploration fieldwork at its Opinaca project, remains committed to cost-effectively assessing mineral potential and advancing its projects towards mineral discovery. This may positively influence revenues and investments into the firm while also bolstering its overall growth.

Targa Exploration (TRGEF), closed Wednesday's trading session at $0.0814, up 27.9472%, on 344,696 volume. The average volume for the last 3 months is 24.985M and the stock's 52-week low/high is $0.0486/$0.38.

Alphabet Inc. (GOOGL)

The Street, InvestorPlace, Kiplinger Today, Zacks, The Online Investor, Schaeffer's, Daily Trade Alert, Investopedia, Trades Of The Day, Market Intelligence Center Alert, Money Morning, MarketBeat, Early Bird, StreetInsider, StreetAuthority Daily, Uncommon Wisdom, MarketClub Analysis, Wealth Insider Alert, Top Pros' Top Picks, Daily Profit, StrategicTechInvestor, The Street Report, Wyatt Investment Research, Wall Street Daily, The Wealth Report, Money and Markets, TopStockAnalysts, CustomerService, AllPennyStocks, Louis Navellier, MarketWatch, StocksEarning, All about trends, Investing Daily, Daily Wealth, ProfitableTrading, TipRanks, Stansberry Research, INO.com Market Report, CNBC Breaking News, Investors Alley, Marketbeat.com, INO Market Report, MarketTamer, MarketArmor.com, Market Intelligence Center, Darwin Investing Network, Power Profit Trades, Trading Tips, Stock Up Featured, InvestorGuide, InsiderTrades, Options Elite, Barchart, QualityStocks, InvestorIntel, Money Wealth Matters, Cabot Wealth, Total Wealth, Daily Dividends, SmallCapNetwork, StockEarnings, DividendStocks, The Night Owl, TheOptionSpecialist, GorillaTrades, Jon Markman’s Pivotal Point, Insider Wealth Alert, Dynamic Wealth Report, FreeRealTime, WStreet Market Commentary, The Daily Market Alert, Investiv, Investing Futures, Short Term Wealth, SmallCap Network, The Weekly Options Trader, Eagle Financial Publications, Investing Signal, Investor Guide, Trader Prep, InvestorsObserver Team, Trade of the Week, Trading Concepts, Market Authority, Average Joe Options, Investing Lab, The Motley Fool, StockMarketWatch, Smartmoneytrading, 24/7 Trader, Jim Cramer, Wealth Daily, TradingPub, Equities.com, The Wall Street Transcript, Investment House, Chaikin PowerFeed, Shah's Insights & Indictments, Financials Trends, Inside Investing Daily, Investing Breakout, Investment U, Earnings360 Newsletter, Stock Barometer, TrendAdvisor, Tradespoon, TradeSmith Daily, Traders For Cash Flow, Top Pros Top Picks, The Trading Report, The Stock Dork, RedChip, BUYINS.NET, ChartAdvisor, Profit Confidential, Lance Ippolito, Mind Over Markets, StockReport, Pennystockmania, CNBC, Contrarian Outlook, Schaeffer’s, bullseyeoptiontrading, BillionDollarClub, Beat The Street, empirefinancialresearch, Earnings360, 360 Wall Street, Day Trade Alert, Candle Stick Forum, Energy and Capital, Economic News Room, Dividend Opportunities, Energy & Resources Digest, StreetAuthority Financial, Rockwell Trading, Roundtable Roundup, SECFilings.com News, SmallCapVoice, Smart Investing Today, Smart Money Press, SmartTrading, Microcapmillionaires, Street Insider, PoliticsAndMyPortfolio.com, Summa Money, SwingTradeOnline, SystemTrading, Technology Profits Daily, Tim Bohen, Tim Sykes, wyatt research newsletter, Stock Gumshoe, Liberty Through Wealth, Greenbackers, HotStockProfits and iDigital Market reported earlier on Alphabet Inc. (GOOGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Udio, an artificial intelligence (AI) music website, seems to be imitating songs written and produced by actual people, flouting the rights of artists globally. This shows how music generated by artificial intelligence is not based on its own creativity but rather by “stealing” the labor and creativity of others.

This explains why earlier this year, artists such as Stevie Wonder, Nicki Minaj, Billie Eilish and Tift Merritt, among others, penned a letter warning that music generated by artificial intelligence trained on their own works could sideline artists and destroy creativity.

The use of artificial intelligence in this way has big record labels worried too. Companies such as Universal Music Group, Sony Music and Warner Music took a step further on this front, suing Udio and Suno over copyright issues.

Suno and Udio both generate content that’s similar to already-produced works. In their defense, both companies denied any violations to existing copyrights, arguing that the suits filed against them were focused on stifling smaller competitors. The companies even went as far as to compare these protests to industry concerns raised in the past about drum machines and synthesizers.

The claims made by Sony and the rest echo allegations by music publishers, news outlets, novelists and others who have also filed copyright suits over chatbots such as Claude and ChatGPT, which use generative artificial intelligence to create text.

These cases, while in different fields, pose new questions for the courts, including whether the law should bend the rules for the use of copyrighted material by AI to create something new.

The cases filed by the record labels, which may take years to settle, also bring up questions unique to music as the interplay of elements, including rhythm and harmony, may make it hard to determine when parts of a song that is copyrighted have been infringed.

In recent court sessions, both AI music companies argued that copyright laws in America protected sound recordings that simulated or imitated other recorded music. Based on this argument, they argued that their works didn’t infringe any copyrights.

The companies also used “fair use” as a defense against these claims of infringement, which raises even more questions. Fair use focuses on promoting freedom of expression by permitting the unauthorized use of works protected by copyrights under certain circumstances.

With artificial intelligence evolving rapidly and creating uncertainties at different levels of copyright law, it remains to be seen how this will play out. Companies that are engaged in creating and training large language models for their generative AI solutions, such as Alphabet Inc. (NASDAQ: GOOGL) (NASDAQ: GOOG), now have to proactively consider whether the material they are using is subject to copyright law so that they don’t get mired in legal battles with parties that feel aggrieved.

Alphabet Inc. (GOOGL), closed Wednesday's trading session at $158.94, up 0.4106387%, on 25,138,573 volume. The average volume for the last 3 months is 7.322M and the stock's 52-week low/high is $120.2057/$191.75.

Trump Media & Technology Group (DJT)

Schaeffer's, QualityStocks, Premium Stock Alerts, 360 Wall Street, Wealth Daily, Early Bird, Tim Bohen, The Street, MarketClub Analysis, Investors Underground, Eagle Financial Publications, Cabot Wealth and AllPennyStocks reported earlier on Trump Media & Technology Group (DJT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trump Media & Technology Group (NASDAQ: DJT), operator of the social-media platform Truth Social, has added linear TV streaming functionality on iOS devices. According to the announcement, iOS users can update their Truth Social apps through the Apple App Store to access TV streaming. After the app has been updated, they can use the new feature by clicking on the Truth+ streaming icon, which looks like a TV and which enables users to stream content as standalone channels or in a separate picture-in-picture (“PiP”) window while on the Truth Social platform.

The addition of streaming on iOS devices is a piece of TMTG’s strategic rollout of its streaming platform: Truth+. Next, the company anticipates releasing streaming apps integrated with the Truth Social platform that will offer features such as an interactive 14-day electronic guide, instant catch-up TV on shows broadcast in the past week, network DVR, video on demand, subscription video on demand, a marketplace and more.

“We’ve hit a big milestone in our TV streaming rollout, with the service now available across the entire Truth Social platform — iOS, Android and the Web,” said Trump Media & Technology Group CEO Devin Nunes in the press release. “Our uncancellable CDN is delivering high-quality TV streaming to all Truth Social users. As we continue to test the service, we look forward to rolling out new Truth+ apps for over-the-top streaming to mobile devices and TVs.”

To view the full press release, visit https://ibn.fm/rtq5E

About Trump Media & Technology Group

Trump Media & Technology Group is on a mission to end Big Tech’s assault on free speech by opening up the internet and giving people their voices back. TMTG operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations. For more information about this company, visit www.TMTGCorp.com.

Trump Media & Technology Group (DJT), closed Wednesday's trading session at $25.72, off by 5.1273%, on 3,016,470 volume. The average volume for the last 3 months is 5.719M and the stock's 52-week low/high is $13.11/$79.38.

Match Group Inc. (MTCH)

InvestorPlace, Schaeffer's, Marketbeat, MarketClub Analysis, StocksEarning, The Street, Kiplinger Today, Daily Trade Alert, Trades Of The Day, StreetInsider, StockEarnings, Trading Tips, Daily Wealth, Money Wealth Matters, Zacks, Stockpalooza, Investopedia, QualityStocks, Stock Stars, Market Intelligence Center Alert, Wealth Insider Alert, The Online Investor, Trading Concepts, Marketbeat.com, Stock Rich, Top Pros' Top Picks, StockHotTips, StockMarketWatch, StreetAuthority Daily, Louis Navellier, HotOTC, OTCReporter, OTC Advisors, CoolPennyStocks, CNBC Breaking News, StockEgg, Penny Invest, SmallCapVoice, Barchart, BUYINS.NET, TopStockAnalysts, The Stock Dork, Wealth Daily, InvestmentHouse, InsiderTrades, GorillaTrades, FreeRealTime, Epic Stock Picks, Energy and Capital, Cabot Wealth, Investment U, StockPickss, Monster Stox, Titan Stocks, PennyOmega, Standout Stocks, Topgun stockpicks, The Trading Report, Early Bird, DividendStocks, wyatt research newsletter, Stock Marketing Inc., Daily Profit, Stock Traders Chat, Chaikin PowerFeed, TipRanks, BloomMoney, XplosiveStocks, The Motley Fool, GusherStocks, SpeculatingStocks, Smart Investing Today, Investiv, Investment House, PennyStockRumors.net, WStreet Market Commentary, Wise Alerts, InvestorsObserver Team, Uncommon Wisdom, OTCPicks, Wall Street Daily, Profit Confidential and Stock Market Watch reported earlier on Match Group Inc. (MTCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Match Group (NASDAQ: MTCH), a leading company in the internet commerce industry, recently reported its quarterly earnings, aligning with the Zacks Consensus Estimate at $0.48 per share, mirroring its performance from the previous year. The company’s revenue for the quarter ending June 2024 was $864.07 million, slightly up from the previous year’s $829.55 million, and exceeded the Zacks Consensus Estimate by 0.92%. This achievement marks the fourth consecutive quarter where Match Group has surpassed consensus revenue estimates, showcasing its consistent performance in a competitive market.

Despite these positive earnings reports, Match Group’s stock has seen a decline of about 9% since the start of the year, underperforming when compared to the S&P 500’s gain of 14.5%. This decline in stock performance, despite the company’s solid revenue growth, highlights the challenges Match Group faces in the stock market. The company’s future stock performance is now under scrutiny, especially with an earnings outlook and recent trend in earnings estimate revisions suggesting a Zacks Rank #4 (Sell), indicating potential underperformance in the near term.

Looking forward, Match Group is expected to achieve an EPS of $0.57 in the next quarter on revenues of $913.68 million, with the full year’s consensus earnings per share projected at $2.11 on $3.55 billion in revenues. These projections are critical for investors as they evaluate the company’s potential for growth amidst the broader internet commerce industry’s performance, which is ranked in the top 25% of over 250 Zacks industries.

On the trading front, Match Group’s stock saw a slight increase of $0.14, or approximately 0.39%, reflecting the volatile nature of the stock market. The stock’s trading range between $35.1 and $36.01 on the day of the report, along with its fluctuation over the past year from a low of $27.655 to a high of $47.81, underscores the stock’s volatility and the broader market’s fluctuating confidence in the internet commerce sector. With a market capitalization of roughly $9.23 billion and a trading volume of 1,058,830 shares, Match Group remains a significant player in its industry, despite the challenges it faces in enhancing shareholder value and navigating market expectations.

To view the company’s latest earnings release, visit https://ibn.fm/xgen0

About Match Group

Match Group, through its portfolio companies, is a leading provider of digital technologies designed to help people make meaningful connections. Its global portfolio of brands includes Tinder(R), Hinge(R), Match(R), Meetic(R), OkCupid(R), Pairs(TM), PlentyOfFish(R), Azar(R), BLK(R), and more, each built to increase its users’ likelihood of connecting with others. Through the company’s trusted brands, it provides tailored services to meet the varying preferences of its users. Match Group’s services are available in over 40 languages to users all over the world.

Match Group Inc. (MTCH), closed Wednesday's trading session at $34.95, off by 2.046%, on 4,954,861 volume. The average volume for the last 3 months is 101,411 and the stock's 52-week low/high is $27.655/$47.81.

Iteris Inc. (ITI)

StreetInsider, Wall Street Resources, InvestorPlace, CRWEPicks, CRWEWallStreet, DrStockPick, PennyToBuck, CRWEFinance, BestOtc, MarketBeat, StockHotTips, SmarTrend Newsletters, PennyOmega, FreeRealTime, StockOodles, Marketbeat.com, QualityStocks, TraderPower, Zacks, Penny Detectives, Stock Traders Chat, StockMarketWatch, The Bowser Report, The Online Investor, FeedBlitz, Trades Of The Day, Trading Concepts, Wealth Insider Alert, BUYINS.NET and SECFilings.com News reported earlier on Iteris Inc. (ITI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Iteris (NASDAQ: ITI), the world’s trusted technology ecosystem for smart mobility infrastructure management, today announced that the City of Lakeland, Florida, has selected it to provide smart mobility infrastructure management technologies to support the city’s Intersection Crash Avoidance Safety Program (“iCASP”). The project includes the deployment of key components of Iteris’ ClearMobility(R) Platform, the world’s most complete solution to monitor, visualize and optimize mobility infrastructure continuously.

According to the announcement, the City of Lakeland initiated this project because of the many crashes attributed to red light running in certain high-impact intersections throughout the city. Therefore, the deployment of Iteris’ advanced technology at 19 of these intersections is expected to enhance security for the traveling public in the city.

“We’re thrilled to be supporting FDOT and the City of Lakeland in their Intersection Collision Avoidance Safety Program,” commented Kevin Exner, regional vice president at Iteris. “This is not only an excellent chance to carry on with our extensive work in the Florida market, but it also combines two of our greatest passions at Iteris: the advancement of ITS infrastructure and the enhancement of road user safety.”

To view the full press release, visit https://ibn.fm/qIQKR

About Iteris Inc.

Iteris is the world’s trusted technology ecosystem for smart mobility infrastructure management. Delivered through its ClearMobility(R) Platform, the company’s AI-powered end-to-end solutions monitor, visualize and optimize mobility infrastructure around the world, and help bridge legacy technology silos to unlock the future of transportations. That’s why more than 10,000 public agencies and private-sector enterprises focused on mobility rely on Iteris every day. For more information about the company, visit www.iteris.com.

Iteris Inc. (ITI), closed Wednesday's trading session at $4.06, off by 0.2457002%, on 61,307 volume. The average volume for the last 3 months is 31.108M and the stock's 52-week low/high is $3.97/$5.49.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, Schaeffer's, StockEarnings, QualityStocks, MarketClub Analysis, The Street, Early Bird, MarketBeat, GreenCarStocks, StocksEarning, Investopedia, INO Market Report, BillionDollarClub, Daily Trade Alert, Trades Of The Day, Kiplinger Today, Money Wealth Matters, The Online Investor, The Wealth Report, Premium Stock Alerts, Louis Navellier, Zacks, FreeRealTime, Green Energy Stocks, The Night Owl, DividendStocks, Wealth Whisperer, Cabot Wealth, Top Pros’ Top Picks, InvestorsUnderground, AllPennyStocks, The Stock Dork, Smartmoneytrading and InsiderTrades reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Chinese automotive giant BYD and American ride-hailing service Uber have revealed that they are teaming up to put a whopping 100,000 battery electric vehicles on roads in major markets outside the United States. A recent Bloomberg report noted BYD is set to provide Uber with tens of thousands of electric cars to run under its ride-hailing service in Canada, Europe, the Middle East, Latin America, New Zealand and Australia, with lower vehicle financing and pricing for drivers.

The United States, currently one of the largest electric-vehicle markets in the world, was conspicuously absent from Uber and BYD’s agreement. This is most likely because the Chinese automakers are largely locked out of the U.S. market. Even so, it represents a significant effort by Uber to electrify its global fleet as dozens of countries worldwide strive to reduce their reliance on fossil fuels in the race to carbon neutrality.

Earlier this year, Uber CEO Dara Khosrowshahi stressed that Uber’s electrification plans were not progressing as speedily as the company initially planned. Many Western automakers have also experienced a notable slowdown in EV sales in recent months, largely due to high electric vehicle prices, high interest rates and rising living costs.

However, while several companies have scaled back their electrification plans in response to the market, Uber is set on putting up to 100,000 EVs on the road in several major markets. The deal is also a significant win for BYD, a Chinese company that has seen explosive growth in recent years and has even given Tesla a run for its money as the largest EV producer on the globe.

After enjoying massive sales within the Chinese market for several years, BYD is now set on expanding into foreign markets where it hasn’t gained a foothold yet. According to BYD Americas chief executive office Stella Li, BYD looks forward to a future where its “cutting-edge electric vehicles” prowl the world’s cities.

However, the two companies will have to navigate an increasingly complex environment before they can bring their plans to fruition. China has all but monopolized the entire EV supply chain and currently has the potential to outcompete foreign carmakers in their markets due to its low EV prices, a fact that has left many Western policymakers quite disconcerted.

Consequently, tensions between the United States and China have been high as America has taken significant steps to keep China out of its budding electric vehicle industry. The European Union has also begun levying import tariffs of up to 38% on Chinese EVs, and Canadian authorities say they are considering similar tariffs.

As more EVs roll onto roads around the world, the overall industry, including companies such as Lucid Motors (NASDAQ: LCID), will benefit from the increased confidence and uptake of these vehicles.

Lucid Motors (LCID), closed Wednesday's trading session at $2.91, off by 5.8252%, on 46,230,854 volume. The average volume for the last 3 months is 29.838M and the stock's 52-week low/high is $2.29/$7.295.

Scorpius Holdings (SCPX)

QualityStocks, Premium Stock Alerts and 360 Wall Street reported earlier on Scorpius Holdings (SCPX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scorpius Holdings (NYSE American: SCPX), an integrated contract-development and manufacturing organization (CDMO), has announced the pricing of an underwritten public offering. The offering is comprised of 12,500,000 shares of common stock or prefunded warrants. Each share of common stock or prefunded warrant is offered at $1. According to the announcement, the company has estimated gross proceeds of approximately $12,500,000, before underwriting discounts and offering expenses are deducted; the proceeds will be used for working capital and general corporate expenses. The company also granted the underwriters a 45-day option to purchase up to 1,875,000 additional shares of common stock and/or prefunded warrants to cover any overallotments. ThinkEquity is acting as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/tLlJ5

About Scorpius Holdings Inc.

Scorpius Holdings is an integrated large-molecule contract-development and manufacturing organization (“CDMO”) focused on rapidly advancing biologic and cell-therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information about the company, please visit www.ScorpiusBiologics.com.

Scorpius Holdings (SCPX), closed Wednesday's trading session at $1.09, off by 80.6394%, on 1,611,380 volume. The average volume for the last 3 months is 51,685 and the stock's 52-week low/high is $1.01/$146.00.

Independence Contract Drilling (ICD)

360 Wall Street and QualityStocks reported earlier on Independence Contract Drilling (ICD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Independence Contract Drilling (NYSE: ICD), a company that provides land-based contract drilling services for oil and natural-gas producers in the United States, is reporting its Q2 2024 financial results for the three-month period ended June 30, 2024. Notable numbers from the report include a net loss of $16.7 million, or $1.15 per share, with adjusted net loss of $10.6 million, or $0.73 per share. Adjusted EBITDA totaled $8.5 million, representing a 28% sequential decrease, with adjusted net debt of $196.7 million, which was a 3% sequential increase. The company also reported that 14.5 average rigs working during the quarter, which was a 4% sequential decrease, with a fully burdened margin per day of $9,675, representing a 18% sequential decrease.

“Our financial results for the second quarter came in line with our expectations, as the overall U.S. land contract drilling market continued to be impacted by elevated rig churn from headwinds driven by customer consolidation, accelerating drilling efficiencies and increased fiscal discipline by E&P customers,” said Independence Contract Drilling CEO Anthony Gallegos in the press release. “These headwinds have continued into the third quarter of 2024 and resulted in the delay or cancellation of expected third-quarter rig reactivation opportunities and additional rig releases where our rigs will be required to be placed with new customers. . . . Assuming our re-contracting efforts are successful, we expect our operating rig count will return to second quarter levels by the end of the fourth quarter of 2024.”

To view the full press release, visit https://ibn.fm/JMuA0

About Independence Contract Drilling Inc.

Independence Contract Drilling provides land-based contract drilling services for oil and natural gas producers in the United States. The company constructs, owns and operates a fleet of pad-optimal ShaleDriller rigs that are specifically engineered and designed to accelerate its clients' production profiles and cash flows from their most technically demanding and economically impactful oil and gas properties. For more information, visit www.ICDrilling.com.

Independence Contract Drilling (ICD), closed Wednesday's trading session at $0.73, off by 39.6694%, on 367,166 volume. The average volume for the last 3 months is 641,479 and the stock's 52-week low/high is $0.7214/$3.45.

Nature's Miracle (NMHI)

360 Wall Street reported earlier on Nature's Miracle (NMHI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nature's Miracle (NASDAQ: NMHI), a growing agriculture-technology company providing equipment and services to growers in the controlled environment agriculture ("CEA") industry, has closed on its previously announced underwritten public offering. The offering was comprised of five million shares of common stock at a public offering price of $0.24 per share. The offering resulted in gross proceeds of $1.2 million, before underwriting discounts and offering expenses were deducted. The underwriter was also granted an option to purchase additional common stock shares of the company and/or warrants. EF Hutton LLC acted as the sole book running manager for the offering.

To view the full press release, visit https://ibn.fm/GZZCy

About Nature's Miracle Holding Inc.

Nature's Miracle is a growing agriculture technology company providing equipment and services to growers in the controlled environment agriculture ("CEA") industry, which also includes vertical farming in North America. Nature's Miracle offers hardware to design, build and operate various indoor growing settings including greenhouses and indoor-growing spaces. Nature's Miracle, through its two wholly owned subsidiaries (Visiontech Group Inc. and Hydroman Inc.), provides grow lights as well as other hydroponic products to hundreds of indoor growers in North America. For more information about this company, visit www.Nature-Miracle.com.

Nature's Miracle (NMHI), closed Wednesday's trading session at $0.1566, off by 3.6308%, on 242,569 volume. The average volume for the last 3 months is 42,511 and the stock's 52-week low/high is $0.15/$3.0399.

The QualityStocks Company Corner

Bebuzee Inc. (OTC: BBUZ)

The QualityStocks Daily Newsletter would like to spotlightFathom Bebuzee Inc. (OTC: BBUZ) .

Bebuzee (OTC: BBUZ), a pioneering force in the realm of social technology, has unveiled a new SuperApp designed to transform the way users interact with technology. According to the announcement, the new app, which will be available Aug. 30, 2024, offers an extensive array of features in a single, seamless platform. Those features include video streaming, photo sharing, instant messaging, short-form videos, global real estate search and e-commerce capabilities.

The company noted that the new app opens unprecedented revenue opportunities. With potential in a wide array of markets, including video ads, sponsored posts, premium subscriptions and more, the app will support Bebuzee's efforts to capture significant market share.

"We are incredibly excited to launch Bebuzee's SuperApp, a platform that will change the way users interact with digital services," said Bebuzee CEO Joe Onyero in the press release. "This launch is not just a milestone for Bebuzee, but a leap forward in the tech industry, promising substantial returns for our investors."

To view the full press release, visit https://ibn.fm/TdxmB

Bebuzee Inc. (OTC: BBUZ), formerly Engage Mobility Inc., is a social platform and streaming service focused on development and deployment of America’s first superapp. The superapp will allow members to watch a wide variety of content, such as movies, series, documentaries and talk shows, on any internet-connected device.

Bebuzee’s technology scans the world’s news, features and information-flow to give its dedicated readers the best of the internet in one place – a one-stop platform for breaking news, interesting and important blogs, videos and photos.

The core features of the superapp include video streaming; photo sharing; Bebuzee Messaging service, which allows users to send text and voice messages and make voice and video calls; Shortbuz, used to make a variety of short-form entertaining videos; Blogbuz, a resource for people without time to scavenge the internet and other sources for news and information; Properbuz global real estate search; global tradesmen search; location reviews of neighborhoods, cities and even regions to help others find their ideal rental or real estate purchase; ShoppingBuz, a unique technology-driven e-commerce platform which gives merchants incredible tools to sell their products; Bebuzee Pay, a mobile payment and digital wallet service that allows users to make mobile payments and online transactions; TravelBuz, an online travel booking service; EventBuz, a ticket exchange and resale platform; and FlightBuz, a flight search engine.

The company is headquartered in Miami.

Introducing the Superapp to Western Markets

A superapp is a mobile phone app that offers a wide range of services within a single platform. This technology allows users to access various services without downloading and switching between multiple apps.

While superapps are popular in many parts of the world, including Latin America, Africa, the Middle East, Asia and Russia, they have achieved little adoption in Western markets. Perhaps the most widely known superapp is WeChat, which is estimated to have as many as 1.24 billion users, mostly in China.

Bebuzee aims to be the first developer to introduce and grow to widespread popularity a superapp in the U.S. and Europe. It took a strong step toward achieving this goal during the COVID-19 pandemic, when Bebuzee’s user base surged by 78% with over 42 million new users.

Whereas most social platforms are generic and only local postings make them somewhat relevant to local communities, Bebuzee has localized its platform for most countries by providing local content, entertainment and information that is frequently updated and refreshed.

The company says the average age of its superapp users is 39, with female users making up 62.8% of its user base. Its monetization strategy includes sales of video advertising, sponsored posts, banner ads and premium listings, as well as promotion of featured brands and property listings.

Market Opportunity

A report from Allied Market Research, a global market research, consulting and advisory firm, estimated that the worldwide superapps market was valued at $58.6 billion in 2022. The report projects the market to expand to $722.4 billion by 2032, growing at a CAGR of 28.9% for the forecast period.

The report identifies a few of the most popular superapps as Rappi in Latin America, Snapp in Iran, Line in Japan and Yandex Go in Russia and Kazakhstan.

Increasing adoption of mobile services and growing advancements in digital technologies are driving the growth of this market. In addition, a rise in government support for promoting the use of superapps is lending to expansion, according to the report.

Integration of blockchain technology in superapps is likewise anticipated to provide numerous opportunities for the expansion of the market during the forecast period, the report states.

Management Team

Joseph Onyero is Founder and CEO of Bebuzee. He has a background of managing multiple products from ideation to market launch and profitable monetization and has been building commercial web presences since 2005. He has worked as a Chief Marketing Officer and in business development. He previously owned and operated a travel and tourism company. He began in 2005 working on the concept and features that have evolved into the Bebuzee suite. He has grown Bebuzee from a living room start-up into a U.S. publicly traded company.

Claudia S. Spagnuolo is Chief Operating Officer at Bebuzee. She began with the company in 2014 as a user experience manager before being promoted to CMO in 2017. She previously worked as an assistant marketing director at the National Secretariat of the union CISL in Italy. Prior to that, she also worked as a researcher at the Complutense University of Madrid on issues of corporate management. She speaks three languages and holds a bachelor’s in political science and a master’s in administration from the University of Perugia in Italy.

Bebuzee Inc. (OTC: BBUZ), closed Wednesday's trading session at $0.1398, up 0.7567568%, on 2,000 volume. The average volume for the last 3 months is 1.442M and the stock's 52-week low/high is $0.01955/$0.359.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

The report explores the growth, competition, and consumer trends, for lesser known cannabinoids

The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion

As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve

With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits, there is a growing interest in edibles infused with non-intoxicating minor cannabinoids. These lesser-known cannabinoids offer unique properties and potential health benefits, driving significant market growth.

BayMedica, a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), specializes in rare cannabinoids, and has published a report on the expansion of the minor cannabinoid market in 2023. Link to a full copy of the report can be found at https://cnw.fm/G09iZ.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Wednesday's trading session at $0.1333, up 8.7276%, on 861,128 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.359/$.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

A research team from the Daegu Gyeongbuk Institute of Science & Technology (DGIST) in South Korea has developed a novel clean-energy-generation technology with self-healing properties. Led by Lee Joo-hyuk, a professor in the department of energy science and engineering, the team designed the biodegradable green device to enhance current renewable energy-generation capabilities while minimizing the burgeoning green-energy industry's impact on the environment. The ionic polyurethane-based triboelectric generator uses ionic liquid to boost its power output significantly and has high electropositive, self healing  and biodegradable properties. The new design's properties make it a potentially feasible sustainable energy source for the next generation of wearable and soft electronic devices. Lee says the team's research efforts led to the development of an efficient material that has both biodegradation and self-healing properties without compromising its high energy output. The researcher said that the prototype would potentially serve as a sustainable power source for the next generation of wearable electric devices and noted that his team would focus on commercializing the technology in its follow-up studies. Many companies, such as FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), are also investing in different ways to make clean energy more widely available at an affordable cost. As these efforts get traction in different markets, fossil fuels are likely to see reduced demand in the years to come.

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Wednesday's trading session at $0.033, up 3.125%, on 259,240 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0258/$0.07.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of Alzheimer's disease.

The news comes as the global Alzheimer's Disease Therapeutics Market is experiencing significant growth as an escalating aging population along with earlier and more accurate diagnoses contribute to more people facing the disease. The article noted that the sector is projected to exceed $30.8 billion by 2033, with a promising CAGR of 18.8% from 2024 to 2033. Biotech and pharma companies active in the space include Pfizer Inc. (NYSE: PFE)Eli Lilly and Company (NYSE: LLY)GSK plc (NYSE: GSK) and Novo Nordisk A/S (NYSE: NVO).

"In 2018, Annovis Bio published data showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer's mouse model," the article stated. "Building on this research, Annovis recently investigated whether combining buntanetap with the GLP-1 agonist dulaglutide would produce a synergistic effect in the same animal model. The results were compelling: while buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination of these two compounds not only restored cognitive function but also enhanced it beyond levels seen in healthy controls."

To view the full press release, visit https://ibn.fm/lXQHw

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

  • Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
  • Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
  • Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
  • Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.
Recent Achievements

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Investment Considerations
  • Unique Market Position: Annovis Bio is uniquely positioned as the only company developing a drug for both AD and PD that inhibits multiple neurotoxic proteins simultaneously.
  • Strong Clinical Results: Buntanetap’s Phase II/III data shows significant cognitive improvement in early AD patients, and the recent Phase III data in PD patients further validates its broad therapeutic potential.
  • Strategic Growth Plans: With recent successful trial results, Annovis Bio is poised for future growth, supported by strong patent protections and upcoming clinical trials.
  • Significant Market Need: As the prevalence of neurodegenerative diseases continues to rise, the demand for effective treatments like buntanetap remains critical.

Annovis Bio continues to advance its mission of developing transformative therapies for neurodegenerative disorders. The company recently announced statistically significant data from its Phase II/III Alzheimer’s study, demonstrating the potential of its lead drug candidate, buntanetap, to improve cognition in patients with early Alzheimer’s Disease (AD). Additionally, the company has released promising data from its Phase III study of buntanetap in patients with early Parkinson’s Disease (PD), which highlights significant advancements in both cognitive and motor functions. These milestones underscore the expanding therapeutic reach of buntanetap.

Annovis Bio Inc. (NYSE: ANVS), closed Wednesday's trading session at $8.02, off by 3.9521%, on 322,863 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.53/$22.49.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"), today released its Q2 2024 financial results. In addition, the company provided recent updates on its CNM-Au8(R) programs evaluating the use of CNM-Au8 for the treatment of ALS and Rett Syndrome. "We are approaching our next FDA interaction focused on the regulatory path forward to potentially bring CNM-Au8 to people living with ALS," commented Rob Etherington, President and CEO of Clene. "With this imminent timing, we are optimistic about the possibility of submitting a new drug application later this year. Our utmost priority is to help patients and their families for whom time is critical."

To view the full press release, visit https://ibn.fm/SA5Kn

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Wednesday's trading session at $4.5, off by 23.4694%, on 484,667 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$15.57.

Recent News

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW)

The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

Recently, Syncio entered into a partnership agreement with Vevol Media to streamline e-commerce operations for businesses by integrating different sales channels. Syncio has, for a while now, been streamlining e-commerce operations for merchants on WooCommerce and Shopify. The company is focused on efficiency and simplicity, while Vevol Media specializes in assisting businesses to thrive in the digital marketplace. Vevol, a leading partner of Shopify, provides a comprehensive range of services, including Shopify design, development, support and marketing. This partnership is a huge step forward in the e-commerce space, combining Vevol's Shopify expertise and Syncio's synchronization tech. It will help deliver a comprehensive solution that addresses the different issues that online retailers face. The collaboration between the two companies attests to the increasing demand for time-saving solutions in the e-commerce space. By combining their strengths, the two companies may become a leading force in assisting businesses to achieve their online sales objectives. Currently, many merchants recommend the Syncio application, citing its ability to sync up to thousands of products as a plus. The app is also easy to set up and manage, and has strong features. This includes a function allowing easy onboarding of vendors or source stores.

It would interesting to hear what established e-commerce players such as NextPlat Corp. (NASDAQ: NXPL) (NXPLW) independently think about the utility of this new solution, introduced by Vevol Media and Snycio.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Alibaba.com Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Wednesday's trading session at $1.02, off by 4.0722%, on 16,350 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.00/$2.96.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today announced John Taylor as president of its commercial EV division. In his new role, Taylor will oversee the company's commercial vehicle operations, including engineering, supply chain management and manufacturing. Taylor, who brings a great breath of experience with a career spanning more than 35 years, also retains his role as senior vice president of global manufacturing for Mullen Automotive. He joined Mullen in 2021 and has played a pivotal role in the development and successful launch of the Mullen ONE Class 1 EV cargo van and Mullen THREE Class 3 low cab forward commercial EV lines which launched in September and November 2023. "John has been an invaluable asset to our company and his promotion to president of Commercial EV division is a testament to his exceptional leadership and contributions," commented David Michery, CEO and chairman of Mullen Automotive. "His proven expertise will be instrumental in driving growth, expanding our market share and achieving our commercial EV business goals."

To view the full press release, visit https://ibn.fm/NyHa2

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.7222, off by 10.8615%, on 15,017,170 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.70/$110.70.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) ("Fr8Tech"), an innovative logistics technology solutions company, today announced the integration of its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine learning that offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, with Tecnomotum, one of the largest data transmission companies for haulage in Mexico. According to the announcement, this integration aims to maximize savings, enhance user experience, provide real-time data, improve fleet connectivity and efficiency, and streamline logistics operations.

"We are proud to offer our customers an even better and more seamless experience. Fr8App's commitment to collaborating with key players in the logistics industry is unparalleled. With each new integration, Fr8App solidifies its position as the most connected and integrable platform for cross-border shipping in the USMCA region. By continuing to partner with industry leaders, Fr8App is leading the way in simplifying logistics processes and enhancing visibility for customers. Our dedication to integration underscores our commitment to delivering the best possible service to customers and is a testament to our continued success in the logistics industry," commented Javier Selgas, CEO of Fr8Tech.

To view the full press release, visit https://ibn.fm/DD4bM

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Wednesday's trading session at $0.178, off by 5.5703%, on 685,940 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.169/$14.00.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

Reporting on environmental, social and governance (ESG) standards in this day and age is important. It encourages accountability and corporate transparency, while also assisting companies in improving resource efficiency. ESG reporting also highlights cost-cutting opportunities and areas for improvement. This is in addition to enabling shareholders to make informed choices and improving brand reputation and loyalty. In addition, ESG reporting offers companies a competitive advantage over other companies. Determining the total number of GHGs produced directly or indirectly from activities carried out by an organization is referred to as carbon accounting. Carbon accounting allows businesses to measure their climate impact as well, aiding in both voluntary and mandatory reporting. By generating important data to help offset and decrease environmental footprints, companies are empowered to build up consumer trust while also fulfilling obligations under their corporate social responsibility. It would be eye opening to see how different companies in different industries, such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), are incorporating ESG in their corporate strategies and how this is either easing or complicating ESG reporting.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Wednesday's trading session at $0.0851, off by 5.4444%, on 9,999 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.1028.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Wednesday's trading session at $0.025625, up 22.0238%, on 10,778 volume. The average volume for the last 3 months is 11,863 and the stock's 52-week low/high is $0.0172/$0.18.

Recent News

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlightFathom Nutriband Inc. (NASDAQ: NTRB) .

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Wednesday's trading session at $5.28, up 6.2374%, on 32,024 volume. The average volume for the last 3 months is 39,862 and the stock's 52-week low/high is $1.53/$9.595.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.187, up 9.1015%, on 12,908,912 volume. The average volume for the last 3 months is 4.408M and the stock's 52-week low/high is $0.153/$6875.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.